BMC Surg16 Nov 2023
In clinical staging for early-stage esophageal cancer, 41.2% of patients experienced upstaging upon final pathology. Tumor size, histology, and delayed esophagectomy (>30 days) were linked to upstaging risk. The rate of achieving optimal oncologic outcomes dropped from 43.8% (reliable clinical staging) to 22.5% (considering upstaging).…
Am Surg15 Nov 2023
In the realm of gastric cancer surgery, a study flexes the stats on surgical approaches. Analyzing 21,015 patients, the research spotlights robotic gastrectomy (RG) as the champ, significantly elevating the likelihood of achieving Textbook Oncologic Outcome (TOO). Minimally invasive gastrectomy (MIG) emerges as a key…
Ann Surg14 Nov 2023
Researchers explored the global landscape of robot-assisted minimally invasive gastrectomy (RAMIG) for gastric cancer in a 2020-2023 registry spanning 25 centers. In 759 cases, RAMIG showcased varying techniques and excellent outcomes. Anastomotic leakage rates after total and distal gastrectomy reflected high surgical quality. The study…
Ann Surg Oncol14 Nov 2023
In a study of 796 preoperative gastric cancer patients, 5.4% had synchronous colorectal cancer (SCRC). Endoscopic treatments were successful, and all SCRC patients underwent curative treatment, with no attributed deaths. Cumulative mortality rates showed 12.6% for gastric cancer-related deaths but none for SCRC. Screening total…
Ann Surg Oncol13 Nov 2023
Researchers belted out a 3-year follow-up tune on the NEOCRTEC-1601 stage, where docetaxel, cisplatin, and fluorouracil (TPF) took the spotlight. For those with borderline-resectable esophageal squamous cell carcinoma (BR-ESCC), the act featured 54.4% survival rates at the 3-year mark. Surgery danced into the spotlight for…
Surg Endosc13 Nov 2023
Researchers staged a retrospective showdown between total omentectomy (TO) and partial omentectomy (PO) in the radical gastrectomy arena for advanced gastric cancer (AGC) with serosal invasion. The verdict? No VIP pass for TO in preventing peritoneal recurrence. PO stole the spotlight with comparable recurrence-free survival…
Langenbecks Arch Surg13 Nov 2023
Researchers lit up esophageal cancer surgery with near-infrared indocyanine green, exposing the elusive thoracic duct (TD) in 94% of cases. Injecting ICG into inguinal nodes during minimal access esophagectomy, the team showcased real-time TD imaging. The glow guided ligation in 16 cases, minimizing chyle leaks…
Gastrointest Endosc12 Nov 2023
Experienced endoscopists seeking competence in endoscopic submucosal dissection (ESD) faced a challenging learning curve. This study introduced an unsupervised training model. Endoscopists initially observed 30 ESD cases and performed 15 unsupervised ex-vivo ESDs. Afterward, they tackled five human distal gastric ESDs and 55 unselected esophago-gastric…
Eur J Surg Oncol12 Nov 2023
Researchers delved into the LOGICA trial, scrutinizing complications after gastric cancer surgery. Comparing Comprehensive Complication Index (CCI) and Clavien-Dindo Classification (CDC), they discovered no significant difference in complication burden between laparoscopic and open D2-gastrectomy. The verdict? While both indices correlated for hospitalization, ICU-stay, and reoperations,…
Surg Endosc10 Nov 2023
The European Association for Endoscopic Surgery conducted a comprehensive review to update guidelines for paraesophageal hernias. They gathered an interdisciplinary panel of experts, including surgeons, gastroenterologists, and patient advocates, and utilized the latest evidence and methodology. Their recommendations emphasize surgery for asymptomatic/minimally symptomatic cases but…